Drug intelligence / Profile preview

BQ-A peptide extract

Development stage: Phase 1
Lead developer: Bioquark
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Intrathecal

Overview

BQ-A is an experimental biologic peptide extract developed by Bioquark Inc., derived from the cytoplasm of oocytes (ooplasms). It contains a complex mixture of bioactive molecules, including microRNAs and proteins, designed to induce neuronal regeneration and cellular reprogramming. The therapy is intended to nurture the growth of new neurons and revert damaged cells into a stem cell-like state. BQ-A is the central component of the ReAnima Project, a controversial multimodality clinical protocol aimed at reversing brain death in patients with traumatic brain injury. It is administered via intrathecal injection and has been studied in combination with mesenchymal stem cells and various stimulation devices.

Brand names: BQ-A peptide extract
Other names: BQ-A Peptide Extract

Beyond the preview

Go deeper on BQ-A peptide extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BQ-A peptide extract.